LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema (DME). DME is a leading cause of adult vision loss, with a significant proportion of patients failing to respond adequately to existing therapies for this condition.
ThromboGenics intends to develop therapeutics based on Bicycle's bicyclic peptides, which inhibit a target involved in vascular permeability. Selective inhibition of this target represents a new approach that offers the potential to improve the treatment of DME. ThromboGenics and Bicycle will collaborate on the preclinical development of these bicyclic peptide inhibitors.
DME is a common consequence of diabetic retinopathy and a leading cause of significantly impaired vision among patients with diabetes. Globally, 350 million people are estimated to suffer from diabetes (WHO). An estimated 30% of all patients suffering from diabetes for over 20 years are at risk of developing DME.For many years, the standard of care has been to treat DME with laser photocoagulation to the macula. More recently, it has been shown that injectable intravitreal drugs that inhibit vascular endothelial growth factor (VEGF) are effective in the treatment of DME. ThromboGenics has gained an exclusive license from Bicycle to undertake clinical development and commercialization of identified drug candidates. ThromboGenics will pay Bicycle an undisclosed upfront fee, development and regulatory milestone payments and royalties on sales of products resulting from the collaboration. Dr Patrik De Haes, CEO of ThromboGenics, said: " This new agreement is further evidence of our commitment to develop and commercialize novel therapeutics targeting unmet needs in the treatment of diabetic eye diseases, such as DME. We are looking forward to evaluating these bicyclic peptides, with the aim of progressing clearly differentiated drug candidates through to the next stages of development. " Commenting on today's announcement, Dr Rolf Guenther, CEO of Bicycle Therapeutics, said: " We have used the Bicycle technology platform to identify and optimize highly selective bicyclic peptides that inhibit a target involved in vascular permeability in the picomolar range. I am delighted to enter this collaboration with Thrombogenics, a partner with a focus and successful track record in developing novel ophthalmic therapeutics, and look forward, in time, to progressing drug candidates into the clinic " . About ThromboGenics
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV